Table 2.
Reason of protocol discontinuation | n = 46 | Post-treatment details | n = 46 | % |
---|---|---|---|---|
Surgery | 8 | R0 resection | 5 | 10.9 |
R2 resection | 3 | 6.5 | ||
Patient's withdrawal | 1 | FOLFIRI + Bmab | 1 | 2.2 |
Disease progression | 1 | FOLFOXIRI + Bmab | 1 | 2.2 |
Adverse event | 9 | FOLFOXIRI ± Bmab | 4 | 8.7 |
FOLFIRI + Bmab | 2 | 4.3 | ||
FL + Bmab | 1 | 2.2 | ||
Capecitabine + Bmab | 1 | 2.2 | ||
BSC | 1 | 2.2 | ||
Protocol completion* | 27 | FOLFOXIRI + Bmab | 18 | 39.1 |
FOLFIRI ± Bmab | 8 | 17.4 | ||
FL + Bmab | 1 | 2.2 |
*Treatment performed in the 12th cycle of protocol therapy
R0 resection curative resection, Bmab bevacizumab, FL infusional 5-fluorouracil and leucovorin, BSC best supportive care